Pre-calving Administration of a Rumensin® Controlled Release Capsule for the Prevention of Energy-Associated Disease

Authors

  • Todd Duffield Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
  • Randal Bagg Provel, Division of Eli Lilly Canada Inc, Guelph, Ontario, Canada
  • Luc DesCôteaux Université de Montreal, Faculté de médecine vétérinaire, Saint-Hyacinthe, Quebec, Canada
  • Emile Bouchard Université de Montreal, Faculté de médecine vétérinaire, Saint-Hyacinthe, Quebec, Canada
  • Marcel Brodeur Université de Montreal, Faculté de médecine vétérinaire, Saint-Hyacinthe, Quebec, Canada
  • Denis DuTremblay Université de Montreal, Faculté de médecine vétérinaire, Saint-Hyacinthe, Quebec, Canada
  • Stephen LeBlanc Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada
  • Greg Keefe Department of Health Management, Atlantic Veterinary College, University of Prince Edward Island
  • Paul Dick Provel, Division of Eli Lilly Canada Inc, Guelph, Ontario, Canada

DOI:

https://doi.org/10.21423/aabppro20015216

Keywords:

metabolic disease, transition, nutritional management, Rumensin controlled release capsule, ketosis, displaced abomasum

Abstract

Since most metabolic disease occurs in the first month of lactation, efforts in prevention have focused on the transition period (six weeks centered around calving). Previous research in Ontario has shown that, in addition to good nutritional management, administration of a Rumensin controlled release capsule (CRC) two to four weeks pre-calving may reduce the incidence of clinical ketosis and displaced abomasum post-calving. The objective of this study was to confirm previous findings of the Rumensin CRC in different herds, regions and years.

Downloads

Published

2001-09-13

Issue

Section

Research Summaries - Dairy

Most read articles by the same author(s)

<< < 3 4 5